APYX

Goodwin Charles D. II

Known title: Chief Executive OfficerCIK: 0001726988

Goodwin Charles D. II's purchase track record

Goodwin Charles D. II has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
11/14/2023APYX$79K+75.3%-6.0%
8/29/2022APYX$70K-70.2%-48.1%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 27, 2026

Apyx Medical featured in cold plasma market growth report. Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.

this person other insiders at APYX

Transaction History

APYX▲ Buy$79K
APYX▲ Buy$12K
APYX▲ Buy$58K

We use analytics to understand how market-wall is used. No personal data is sold.